LBT Innovations Limited

Equities

LBT

AU000000LBT8

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 05:34:40 23/05/2024 am IST			5-day change	1st Jan Change
0.018 ^AUD	0.00%		+12.50%	+63.64%

08/05	Transcript : LBT Innovations Limited, Q3 2024 Earnings Call, May 08, 2024
29/04	LBT Innovations Sells APAS Independence Instrument to NovaCina	MT

LBT Innovations Limited entered into binding agreement to acquire remaining 50% stake in Clever Culture Systems AG from Hettich Holding Beteiligungs- und Verwaltungs GmbH for AUD 4 million.

December 29, 2021

LBT Innovations Limited (ASX:LBT) entered into binding agreement to acquire remaining 50% stake in Clever Culture Systems AG from Hettich Holding Beteiligungs- und Verwaltungs GmbH for AUD 4 million on December 29, 2021. The consideration consists of AUD 1 million in cash, 30.66 million shares and 8 million options at AUD 0.25 per share. LBT Innovations will also acquire AUD 17.3 million shareholders loan of Hettich Holding Beteiligungs- und Verwaltungs GmbH.

The transaction is expected to close by December 31, 2021.

Latest news about LBT Innovations Limited

Transcript : LBT Innovations Limited, Q3 2024 Earnings Call, May 08, 2024	08/05
LBT Innovations Sells APAS Independence Instrument to NovaCina	29/04	MT
Australian Shares Track Gains of Wall Street Peers as Market Shrugs Off US Inflation Data	13/03	MT
LBT Innovations' APAS PharmaQC Completes Primary Validation; Shares Up 79%	13/03	MT
Transcript : LBT Innovations Limited, Q2 2024 Earnings Call, Feb 29, 2024	29/02
LBT Innovations Delivers APAS Hardware, Software to Thermo Fisher	23/02	MT
LBT Innovations Limited Reports Earnings Results for the Half Year Ended December 31, 2023	23/02	CI
LBT Innovations Makes First Sale of APAS PharmaQC; Shares Jump 31%	22/02	MT
LBT Innovations Limited Appoints Dan Hill as Non-Executive Director	14/12	CI
LBT Innovations Limited Announces Retirement of Damian Lismore as Director. Effective 29 November 2023	27/11	CI
LBT Innovations Secures Approval for AU$1.7 Million Loan Restructuring	06/11	MT
LBT Innovations Fully Repays Share Placement Facility	13/23/13	MT
LBT Innovations Raising Up to AU$4.5 Million Via Entitlement Offer; Shares Down 27%	13/23/13	MT
LBT Innovations Secures R&D Tax Refund for Fiscal Year 2023; Shares Rally 11%	05/23/05	MT
LBT Innovations Limited Reports Earnings Results for the Full Year Ended June 30, 2023	31/23/31	CI
LBT Innovations Flags AU$13 Million Impairment Charge	04/23/04	MT
LBT Innovations Limited Appoints Rebecca Wilson as Director	05/23/05	CI
LBT Innovations Appoints Chair; Shares Jump 7%	03/23/03	MT
LBT Innovations Limited Announces the Retirement of Simon Arkell as Non-Executive Director	30/23/30	CI
LBT Innovations Limited Reports Earnings Results for the Half Year Ended December 31, 2022	28/23/28	CI
Transcript : LBT Innovations Limited, Q2 2023 Earnings Call, Jan 25, 2023	25/23/25
LBT Innovations, AstraZeneca Partner to Develop APAS Pharma Product	09/23/09	MT
Astrazeneca Partners LBT for Apas Pharma Development	09/23/09	CI
LBT Innovations Limited Receives an Initial Purchase Order from Thermo Fisher Scientific, Inc	20/22/20	CI
LBT Innovations Subsidiary Appoints Thermo Fisher as Exclusive Distributor for Europe	19/22/19	MT

Chart LBT Innovations Limited

Duration

Period

More charts

Company Profile

LBT Innovations Limited is a medical technology company. The Company is engaged in researching, developing and commercializing technologies for the healthcare and laboratory supply markets and manufacture and sales of the Automated Plate Assessment System (APAS Independence). Its products include APAS Independence, APAS Analysis Modules, APAS-AMR Analysis Module, and APAS PharmaQ. The APAS Independence is a platform technology that automates culture-plate screening and interpretation. The APAS Analysis Modules are the intelligent image analysis software that works together with the APAS Independence to enable the screening of microbiology culture plates. The APAS-AMR Analysis Module uses artificial intelligence mage analysis platform to read and interpret antimicrobial susceptibility tests (ASTs) for the detection of antimicrobial resistance (AMR). The APAS PharmaQC provides automated imaging, analysis and interpretation of microbiology culture plates used in environmental monitoring.

Sector

Biotechnology & Medical Research

Calendar

29/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
LBT INNOVATIONS LIMITED	+63.64%	1.6Cr
MODERNA, INC.	+67.53%	6.39TCr
IQVIA HOLDINGS INC.	-0.77%	4.18TCr
LONZA GROUP AG	+45.66%	4.07TCr
CELLTRION, INC.	-10.72%	2.71TCr
ICON PUBLIC LIMITED COMPANY	+13.30%	2.65TCr
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	1.87TCr
BIO-TECHNE CORPORATION	+4.70%	1.27TCr
UNITED THERAPEUTICS CORPORATION	+24.10%	1.21TCr
MEDPACE HOLDINGS, INC.	+27.41%	1.21TCr

Other Biotechnology & Medical Research